UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

Clinical infectious diseases, 2020-04, Vol.70 (8), p.1525-1533

2020

Volltextzugriff (PDF)

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

American journal of transplantation, 2020-06, Vol.20 (6), p.1703-1711

2020

Volltextzugriff (PDF)

Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries

EClinicalMedicine, 2020-06, Vol.23, p.100401-100401, Article 100401

2020

Volltextzugriff (PDF)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial

Human vaccines & immunotherapeutics, 2021-07, Vol.17 (7), p.1980-1985

2021

Volltextzugriff (PDF)

Seizure with Acute Pulmonary Infiltrates

The American journal of medicine, 2011-11, Vol.124 (11), p.e1-e2

2011

Volltextzugriff (PDF)

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

The New England journal of medicine, 2017-12, Vol.377 (25), p.2433-2444

2017

Volltextzugriff (PDF)

Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet. Haematology, 2024-02, Vol.11 (2), p.e127-e135

2024

Volltextzugriff (PDF)

Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients

Clinical pharmacology and therapeutics, 2022-02, Vol.111 (2), p.485-495

2022

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients

The Pediatric infectious disease journal, 2024-03, Vol.43 (3), p.203

2024

Volltextzugriff (PDF)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

Journal of acquired immune deficiency syndromes (1999), 2019-12, Vol.82 (4), p.e47-e49

2019

Volltextzugriff (PDF)

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial

PharmacoEconomics - open, 2021-09, Vol.5 (3), p.469-473

2021

Volltextzugriff (PDF)

Letermovir Prophylaxis for Cytomegalovirus

The New England journal of medicine, 2018-03, Vol.378 (10), p.963-965

2018

Volltextzugriff (PDF)

INH Hepatotoxicity, A Cause of Fulminant Hepatic Failure: A Case Report: 829

The American journal of gastroenterology, 2011-10, Vol.106, p.S309

2011

Volltextzugriff (PDF)

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Volltextzugriff (PDF)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended from 100 to 200 Days Post-Transplant in Cytomegalovirus (CMV)-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S64

2023

Volltextzugriff (PDF)

76 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended from 100 to 200 Days Post-Transplant in Cytomegalovirus (CMV)-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Transplantation and cellular therapy, 2023-02, Vol.29 (2), p.S64-S64

2023

Volltextzugriff (PDF)

623. Preliminary Dosing for Adolescent Hematopoietic Stem-Cell Transplant (HSCT) Recipients Based on Pharmacokinetic (PK), Safety, and Efficacy Data of Letermovir (LET) for Cytomegalovirus (CMV) Prophylaxis

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Volltextzugriff (PDF)

Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Brain Abscess: A Case Report and Review of Literature

Infectious diseases in clinical practice (Baltimore, Md.), 2011-11, Vol.19 (6), p.392-394

2011

Volltextzugriff (PDF)

The Leader Polypeptide of Theiler's Murine Encephalomyelitis Virus Is Required for the Assembly of Virions in Mouse L Cells

Journal of Virology, 2000-01, Vol.74 (2), p.875-882

2000

Volltextzugriff (PDF)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S56-S57

2018

Volltextzugriff (PDF)

Austrian Syndrome (Triad of Pneumococcal Pneumonia, Meningitis and Endocarditis) in an Intravenous Drug User: A Case Report

Infectious diseases in clinical practice (Baltimore, Md.), 2010-11, Vol.18 (6), p.406-407

2010

Volltextzugriff (PDF)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S311-S311

2017

Volltextzugriff (PDF)

No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil

Biology of blood and marrow transplantation, 2015-02, Vol.21 (2), p.S243-S243

2015

Volltextzugriff (PDF)

The leader polypeptide of Theiler's virus is essential for neurovirulence but not for virus growth in BHK cells

Journal of Virology, 1995-09, Vol.69 (9), p.5544-5549

1995

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(25)
Dissertationen
(1)

Sprache

Englisch
(26)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(10)
Adult
(7)
Cytomegalovirus
(6)
Cytomegalovirus Infections - Prevention & Control
(6)
Immunology
(6)
Adolescent
(5)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(5)
Male
(5)
Medicin Och Hälsovetenskap
(5)
Female
(4)
Infectious Diseases
(4)
Microbiology
(4)
Quinazolines
(4)
Acetates
(3)
Acetates - Adverse Effects
(3)
Antiviral Agents - Therapeutic Use
(3)
Antiviral Drugs
(3)
Double-Blind Method
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial

Seizure with Acute Pulmonary Infiltrates

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Exposure–Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients

Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial

Letermovir Prophylaxis for Cytomegalovirus

INH Hepatotoxicity, A Cause of Fulminant Hepatic Failure: A Case Report: 829

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended from 100 to 200 Days Post-Transplant in Cytomegalovirus (CMV)-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

76 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended from 100 to 200 Days Post-Transplant in Cytomegalovirus (CMV)-Seropositive Recipients (R+) of an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

623. Preliminary Dosing for Adolescent Hematopoietic Stem-Cell Transplant (HSCT) Recipients Based on Pharmacokinetic (PK), Safety, and Efficacy Data of Letermovir (LET) for Cytomegalovirus (CMV) Prophylaxis

Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Brain Abscess: A Case Report and Review of Literature

The Leader Polypeptide of Theiler's Murine Encephalomyelitis Virus Is Required for the Assembly of Virions in Mouse L Cells

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients

Austrian Syndrome (Triad of Pneumococcal Pneumonia, Meningitis and Endocarditis) in an Intravenous Drug User: A Case Report

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)

No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil

The leader polypeptide of Theiler's virus is essential for neurovirulence but not for virus growth in BHK cells

Suchergebnisse filtern